Vimarsana
Biggest News Aggregation in the World

Mcommercialization Readiness Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mcommercialization Readiness Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mcommercialization Readiness Program Today - Breaking & Trending Today

RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures - Vimarsana News

RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures

LOWELL, Mass.--(BUSINESS WIRE)--Oct 6, 2023--

A better bridge across the 'valley of death' - Vimarsana News

A better bridge across the 'valley of death'

As the Pentagon’s Small Business Strategy makes clear, small companies are key to helping the U.S. ensure its technological superiority.

Alume Receives Commercialization Readiness Program Grant from the NIH to Support Commercialization of ALM-488 to Highlight Nerves - Vimarsana News

Alume Receives Commercialization Readiness Program Grant from the NIH to Support Commercialization of ALM-488 to Highlight Nerves

/PRNewswire/ -- Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced today that it has been awarded a $3.4M...

Alume Receives Commercialization Readiness Program Grant from the NIH to Support Commercialization of ALM-488 to Highlight Nerves - Vimarsana News

Alume Receives Commercialization Readiness Program Grant from the NIH to Support Commercialization of ALM-488 to Highlight Nerves

/PRNewswire/ -- Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced today that it has been awarded a $3.4M...

Vaxess Technologies Awarded NIH Grant of up to $2.85 Million to Drive MIMIX™ Sustained Release Vaccine Patch Into a 2022 Phase 1 Human Trial - Vimarsana News

Vaxess Technologies Awarded NIH Grant of up to $2.85 Million to Drive MIMIX™ Sustained Release Vaccine Patch Into a 2022 Phase 1 Human Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 22, 2021-- Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intradermal microneedle patch, announced it was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH). Vaxess will receive up to $2.85 million over the course of the award if the project milestones are met. The CRP grant will be used to advance the co...